Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Assets (2016 - 2025)

Historic Assets for Viking Therapeutics (VKTX) over the last 12 years, with Q4 2025 value amounting to $715.7 million.

  • Viking Therapeutics' Assets fell 2120.31% to $715.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $715.7 million, marking a year-over-year decrease of 2120.31%. This contributed to the annual value of $715.7 million for FY2025, which is 2120.31% down from last year.
  • Latest data reveals that Viking Therapeutics reported Assets of $715.7 million as of Q4 2025, which was down 2120.31% from $739.4 million recorded in Q3 2025.
  • Viking Therapeutics' Assets' 5-year high stood at $967.5 million during Q1 2024, with a 5-year trough of $150.9 million in Q1 2023.
  • For the 5-year period, Viking Therapeutics' Assets averaged around $492.4 million, with its median value being $375.6 million (2023).
  • Its Assets has fluctuated over the past 5 years, first plummeted by 2574.51% in 2022, then skyrocketed by 54118.63% in 2024.
  • Over the past 5 years, Viking Therapeutics' Assets (Quarter) stood at $210.7 million in 2021, then dropped by 20.0% to $168.5 million in 2022, then surged by 118.65% to $368.5 million in 2023, then surged by 146.5% to $908.3 million in 2024, then decreased by 21.2% to $715.7 million in 2025.
  • Its Assets stands at $715.7 million for Q4 2025, versus $739.4 million for Q3 2025 and $827.9 million for Q2 2025.